You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The PCR-based test received EUA for use on the Alinity m platform after receiving authorization in March on the firm's m2000 RealTime System.
The Boston-based firm is developing a bacterial diagnostic platform to detect antibiotic resistance and help guide antibiotic treatment in hospitals.
The firm said its test is one-thousandfold more sensitive than conventional SARS-CoV-2 serology tests and could enable earlier antibody detection in patients.
According to the company, its ArrayPlex platform can screen patient samples for anti-SARS-CoV-2 antibodies at a rate of 18,000 samples per instrument per day.
Meridian has been providing essential components, including reagents, for multiple SARS-CoV-2 molecular and serology tests.
The PCR-based tests are designed to detect the SARS-CoV-2 nucleocapsid gene in various respiratory specimens including oropharyngeal swabs.
The Boston-based startup will use the funding to flesh out its diagnostic platform to detect antibiotic-resistant bacterial infections within a clinically relevant timeframe.
The company is creating a high-throughput NGS test for healthcare workers and the underserved, and to support viral surveillance programs for large employers.
The federal agency approved the use of the Zymo Research SARS-CoV-2 kit with both upper respiratory and lower respiratory specimens.
SARS-CoV-2 might have resulted from recombination between pangolin and bat coronaviruses, with pangolins serving as an intermediate host.
The test is validated and authorized for numerous extraction technologies and PCR instruments.
The firm anticipates using the proceeds for working capital and general corporate purposes, and to pay the net cost of convertible-note hedge transactions.
The firm recently announced a collaboration with Sweden’s Karolinska Institute to test COVID-19 pneumonia patients for bacterial co-infections.
Fluidigm's mass cytometry and microfluidics research product sales were negatively impacted by the COVID-19 pandemic.
The company saw orders for its Cologuard colorectal cancer test fall 63 percent during the first 20 days of April because of a decline in standard healthcare visits.
The multiplex RT-PCR test simultaneously detects two target sequences inside the SARS-CoV-2 N gene, providing results in about two hours.
The system is approved for use with the Procleix Ultrio Elite Assay, the Procleix WNV Assay, Procleix Zika Virus Assay, and the Procelix Babesia Assay.
The informatics firm is working on an RUO COVID-19 susceptibility risk score to inform researchers and policymakers itching to restart the US economy.
The kit is designed to detect viral RNA extracted from various respiratory samples including sputum, providing results within three and a half hours.
Danaher President and CEO Thomas Joyce will retire in September and will be replaced by Rainer Blair, the current executive VP of the life sciences division.
The Washington Post reports that the CDC's SARS-CoV-2 test issues reflect earlier ones it had with Zika virus testing.
NPR writes that even with thousands of new COVID-19 papers, each should be evaluated based on its own quality.
Researchers traced a gene cluster linked to COVID-19 severity to Neanderthals, the New York Times reports.
In PNAS this week: soil bacteria-derived small molecules affect centrosomal protein, microfluidics approach for capturing circulating tumor cells, and more.